EPBIO.BO EP Biocomposites up 9.89% intraday on BSE 26 Jan 2026: outlook
EPBIO.BO stock jumped to INR 98.90 on BSE in intraday trade, rising 8.90 points or 9.89% on 26 Jan 2026. The move follows low-volume buying with 500.00 shares traded versus an average volume of 2,328.00. Traders are watching valuation and liquidity metrics as price tests the 50-day and 200-day averages. We examine why EP Biocomposites Ltd. (EPBIO.BO) led intraday gainers and what that means for short-term traders and longer-term investors.
EPBIO.BO stock intraday move and immediate drivers
EPBIO.BO stock opened at INR 98.90 and matched the day high. The rise of 9.89% on low volume suggests selective buying rather than broad demand. Volume was 500.00 versus average volume 2,328.00, giving a relative volume of 0.21. Traders noted the prior close at INR 90.00, so the intraday gap reflects short-covering and a technical bounce.
Fundamentals snapshot for EP Biocomposites Ltd. (EPBIO.BO)
EP Biocomposites reports EPS INR 5.45 and a trailing PE of 18.15. Book value per share is INR 63.11 and price-to-book is 1.57, indicating modest premium to net assets. Key ratios show a healthy current ratio 3.95 and interest coverage 8.76, supporting financial stability. Revenue per share is INR 59.05 and net margin is 9.36%, linking earnings to the current price move.
Technical picture and sector context for EPBIO.BO stock
Technicals show neutral momentum: RSI 47.80 and MACD histogram positive at 1.67. The 50-day average is INR 112.52 and the 200-day average is INR 119.11, both above current price, indicating the stock is below medium-term trend. Bollinger mid is INR 100.96 with upper band INR 114.85. The Industrials sector is weaker year-to-date, pressuring peers and setting a cautious backdrop.
Meyka AI grade and forecast for EPBIO.BO
Meyka AI rates EPBIO.BO with a score of 63.88 out of 100: B – HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of INR 73.71 versus the current INR 98.90, implying an expected change of -25.47%. Forecasts are model-based projections and not guarantees. For details visit the company site EP Biocomposites and our internal page Meyka EPBIO.BO stock.
Risks and opportunities for EPBIO.BO stock
Opportunity: low debt-to-equity 0.28 and strong working capital of INR 105,384,000.00 support expansion. Risk: receivables days at 404.18 inflate the cash conversion cycle to 366.59 days and constrain liquidity. Market cap is INR 166,371,558.00 and average daily turnover is thin, raising execution risk for large orders.
Trading view, price targets and liquidity notes for EPBIO.BO stock
Short-term traders can target a resistance band near INR 114.85–115.00 and watch support at INR 90.00 and INR 75.00. We set a conservative near-term price target of INR 115.00 and a downside risk target around INR 75.00 if selling accelerates. Note the low free float and average volume 2,328.00 can widen spreads and increase volatility during news events.
Final Thoughts
EPBIO.BO stock led intraday gainers on 26 Jan 2026, rising to INR 98.90 on a 9.89% jump. The rally appears technical given low volume. Fundamentals are mixed: reasonable PE 18.15, book value INR 63.11, and strong liquidity ratios, but stretched receivables and a long cash conversion cycle increase operating risk. Meyka AI’s forecast model projects INR 73.71 over one year, implying -25.47% from the current price; this highlights divergence between short-term momentum and model-driven fair value. Traders seeking quick gains should limit position size and use stop-loss near INR 90.00. Longer-term investors should wait for improved receivables turnover or clearer revenue momentum before adding exposure. Meyka AI provides this as an AI-powered market analysis platform view, not investment advice. Forecasts are model-based projections and not guarantees.
FAQs
What drove EPBIO.BO stock higher today?
Selective buying and technical short-covering drove EPBIO.BO stock to INR 98.90, up 9.89%. Volume was light at 500.00, so the move looks tactical rather than fundamental.
How does EP Biocomposites look on valuation?
EPBIO.BO shows a trailing PE of 18.15 and PB of 1.57. These metrics place it at modest valuation versus book, but analysts note weak receivables and low liquidity as valuation constraints.
What is Meyka AI’s view on EPBIO.BO stock?
Meyka AI rates EPBIO.BO 63.88/100 (Grade B, HOLD) and projects INR 73.71 yearly. The grade factors sector, growth, and key metrics. Forecasts are model-based and not guarantees.
Are there clear price targets for traders?
Near-term resistance is INR 114.85–115.00 and support is INR 90.00 and INR 75.00. Low average volume requires tight risk controls and conservative position sizing.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
